A Swedish biotechnology company announced Tuesday it has secured a licensing agreement worth up to $134 million for its kidney transplant medication, providing crucial funding as the firm awaits potential U.S. regulatory approval later this year.
Hansa Biopharma revealed the partnership with privately held SERB Pharmaceuticals will grant the company exclusive rights to market and develop Idefirix across Europe and several other international markets. The financial boost is expected to sustain the biotech firm through profitability while maintaining investment in additional drug development projects.
The arrangement positions Hansa for a strong U.S. market entry, contingent on approval from the U.S. Food and Drug Administration, with a regulatory decision anticipated in December. SERB Pharmaceuticals will gain exclusive development and marketing authority for Idefirix throughout the European Union, Britain, Switzerland, Norway, Liechtenstein, Iceland, the Middle East and North Africa.
Idefirix, scientifically known as imlifidase, works by rapidly eliminating immunoglobulin G antibodies that can trigger immune system rejection of transplanted kidneys. The medication currently holds conditional approval across the EU, Norway, Liechtenstein, Iceland and the UK, with full approval granted in Australia and Switzerland.
The financial structure includes an immediate payment of 110 million euros to Hansa, with an additional 5 million euros due when the European Medicines Agency accepts the company’s full approval application for review. SERB Pharmaceuticals will assume complete responsibility for future development and marketing efforts.
Market analysts from Jefferies project the drug could generate approximately 1.08 billion Swedish crowns in sales by 2027, assuming U.S. regulatory approval is obtained. Following the announcement, Hansa’s stock price surged as much as 30 percent during early trading on the Stockholm exchange Tuesday.
